Southern Therapy and Advanced Research LLC

Industry / private company


Location: Jackson, MS

ISNI: -

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial (2019) Dalekos G, Invernizzi P, Nevens F, Hans VV, Zigmond E, Andrade RJ, Ben Ari Z, et al. Conference contribution Treatment efficacyand safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12-and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study (2018) Hirschfield G, Boudes P, Bowlus C, Gitlin N, Michael G, Harrison S, Gordon SC, et al. Conference contribution Efficacy and Safety of Seladelpar, a Selective Peroxisome Proliferator-Activated Receptor Delta Agonist, in Primary Biliary Cholangitis: 52-Week Analysis of an Ongoing International, Randomized, Dose Ranging Phase 2 Study (2018) Bowlus CL, Neff GW, Aspinall R, Galambos MR, Goel A, Hirschfield G, Kremer A, et al. Conference contribution Effect of Seladelpar on Pruritus in Primary Biliary Cholangitis: 26-Week Analysis of an Ongoing International, randomized, Dose Ranging Phase 2 Study (2018) Kremer A, Bowlus CL, Neff GW, Aspinall R, Galambos MR, Goel A, Hirschfield G, et al. Conference contribution